Gilead Sciences Inc.'s ongoing strategy to diversify its pipeline scored a small victory with the approval of inhaled aztreonam lysine drug Cayston, but there's no question the firm's future growth still hinges largely on its next-generation HIV pipeline. (BioWorld Today) Read More
